You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Colorcon
Baxter
Mallinckrodt
McKesson

Last Updated: September 22, 2020

DrugPatentWatch Database Preview

Patent: 9,895,428

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,895,428
Title:Methods of treating antibody-mediated rejection in organ transplant patients with C1-esterase inhibitor
Abstract: A method and composition for treating or preventing antibody-mediated rejection (AMR) of a transplanted organ are provided.
Inventor(s): Broom; Colin (Devon, PA), Uknis; Marc E. (Chadds Ford, PA)
Assignee: Shire Viropharma Incorporated (Lexington, MA)
Application Number:14/550,075
Patent Claims:see list of patent claims

Details for Patent 9,895,428

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial Shire Viropharma Incorporated (Lexington, MA) 2033-11-22 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial Shire Viropharma Incorporated (Lexington, MA) 2033-11-22 RX search
Alexion Pharm SOLIRIS eculizumab INJECTABLE; IV (INFUSION) 125166 001 2007-03-16   Start Trial Shire Viropharma Incorporated (Lexington, MA) 2033-11-22 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial Shire Viropharma Incorporated (Lexington, MA) 2033-11-22 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial Shire Viropharma Incorporated (Lexington, MA) 2033-11-22 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Johnson and Johnson
Dow
AstraZeneca
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.